The Flare in Serum Alkaline Phosphatase Activity After Orchiectomy: A Valuable Negative Prognostic Index for Progression-Free Survival in Prostatic Carcinoma
- 1 July 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 156 (1) , 122-126
- https://doi.org/10.1016/s0022-5347(01)65962-7
Abstract
We determined whether an early flare in serum alkaline phosphatase activity after orchiectomy was of prognostic value for progression-free survival in patients with advanced prostatic carcinoma. A retrospective analysis of a data base from a Dutch multicenter study on prostatic carcinoma was done to determine the prognostic value of a flare in alkaline phosphatase activity after orchiectomy in 112 patients with metastatic (75 percent) or locally advanced (25 percent) disease. Cox's proportional hazards models and Kaplan-Meier survival curves were used. Of the patients 50 percent had initially increased alkaline phosphatase levels and a flare in activity was demonstrated in 87 percent 2 to 4 weeks after orchiectomy. The prostate specific antigen nadir (cutoff 4 ng./ml.) 6 months after orchiectomy was of significant prognostic value for progression-free survival. A flare in alkaline phosphatase activity after orchiectomy demonstrated an early significant prognostic value for progression-free survival, independent of the serum alkaline phosphatase activity. The simplicity, ready availability and cost-effectiveness of serum alkaline phosphatase activity as a prognostic index render it attractive to the clinician, particularly early in the course of prostatic carcinoma. Measuring the flare in alkaline phosphatase activity within 1 month of orchiectomy may permit early identification of patients in whom the disease is likely to progress rapidly and who would potentially benefit from aggressive treatment.Keywords
This publication has 18 references indexed in Scilit:
- The Clinical Usefulness of Prostate Specific Antigen: Update 1994Journal of Urology, 1994
- Doxorubicin, Mitomycin C and 5-Fluorouracil in the Treatment of Hormone Refractory Adenocarcinoma of the Prostate: A Southwest Oncology Group StudyJournal of Urology, 1993
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1990
- Total Bone Uptake in Management of Metastatic Carcinoma of the ProstateJournal of Urology, 1987
- Biochemical Markers and Skeletal Metabolism in Carcinoma of the Prostate: Use of Decision Matrix Theory and ROC AnalysisBritish Journal of Urology, 1985
- The flare phenomenon on radionuclide bone scan in metastatic prostate cancerAmerican Journal of Roentgenology, 1984
- Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma.Radiology, 1983
- Serial Bone Scans in the Assessment of Response to Therapy in Advanced Breast CarcinomaClinical Nuclear Medicine, 1982
- Serial Bone Scanning Using Technetium 99m Diphosphonate in Patients Undergoing Cyclical Combination Chemotherapy for Advanced Breast CancerClinical Nuclear Medicine, 1976